Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. - Wikidata - awgldk - TriplyDB

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33627763

about

Aflibercept New perspectives in glioblastoma antiangiogenic therapy Tumor refractoriness to anti-VEGF therapy Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data Anti-angiogenic agents in metastatic colorectal cancer Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer Broad targeting of angiogenesis for cancer prevention and therapy Horizons in therapy for corneal angiogenesis.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Pharmacokinetics of Anti-VEGF Agent Aflibercept in Cancer Predicted by Data-Driven, Molecular-Detailed Model.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Ziv-aflibercept use in metastatic colorectal cancer.Investigational agents in development for the treatment of ovarian cancer Emerging treatment options for patients with castration-resistant prostate cancer.Personalizing medicine for metastatic colorectal cancer: current developments.Targeting lymphatic vessel functions through tyrosine kinases.Bevacizumab increases risk for severe proteinuria in cancer patients.Regorafenib: from bench to bedside in colorectal cancer.Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.Antibody-based therapeutics to watch in 2011.Targeted therapy in prostate cancer.Aflibercept in the treatment of metastatic colorectal cancer.Ziv-aflibercept in metastatic colorectal cancer Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC Development of novel DNA vaccine for VEGF in murine cancer model Applications of molecular imaging.Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study Angiogenesis in acute myeloid leukemia and opportunities for novel therapies.Quantitative effects of using compressed sensing in dynamic contrast enhanced MRI Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin Targeted therapies for non-small cell lung cancer: an evolving landscape.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future Robustness of quantitative compressive sensing MRI: the effect of random undersampling patterns on derived parameters for DCE- and DSC-MRI Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

P2860

Q24600199-B1B36B0F-AEE3-4EF8-825A-87A8D1BB9661 Q26746028-DD2F0EEC-F107-444B-815E-0EEF47229FFC Q26747678-506D4191-D712-4DC6-8EFE-3EEAB14AACD9 Q26781098-BB9CBDDA-DA9E-4033-9BC7-E3DAC81CB1C2 Q26801911-97D6392B-16B2-45CB-828C-BDA588F3E1EA Q26830219-A9FE062D-0F82-40E3-A1B1-A7140CE48D1B Q27002903-D2E139D0-214E-4493-BF36-AE609DE7EB32 Q27691454-63BCD729-825A-4ED9-91BA-BAE76B5FB7F5 Q30417015-A5BB87D9-5594-4811-83A6-71F1E2442340 Q30424925-FA5DAE7C-928C-4477-9A26-48342A5DEBFB Q30455612-8A12CDC0-19F2-42A9-92CE-D072BBE91181 Q31037873-355B551C-7665-41D0-B490-E58F8B5EBC57 Q33410375-527F412D-1163-4F05-9346-B350AEFA681A Q33886059-682087B8-B4CE-47B7-8ED7-CD0B6F0DC7D5 Q33920800-64628B6C-8E1C-4D35-B8A5-4DF6B9BE279C Q33958519-CD57332B-AE55-4CA6-986C-B290C4E1743A Q34036665-6FC33BD6-3184-4EFD-A370-959C89470E2F Q34078275-8672537C-13A6-4D42-8A54-263FF204F1A2 Q34124173-1A06F232-E0C6-4765-A273-17A3E6E4B376 Q34343524-B18C9DA1-1E8D-4991-8653-EFB058F99C26 Q34348270-69E827F3-D139-41BB-9F2C-3DAB52BD1E57 Q34570079-E1DB5821-18B7-4807-BB42-254F7EAF559D Q34634763-F857F306-F276-46B5-BFC6-DF000A8A069A Q34635176-FEEF87B8-87D5-4D29-A55C-BA0032068B44 Q34658579-FD9B4BFF-8774-417F-AA44-842D54D726EA Q34658699-A248AD4D-E240-4D65-9DDB-537FA4B3C493 Q35050210-E7A2E493-C662-4A1A-9E5F-25A3D3A4ACBB Q35056226-2E05DD61-8F97-41A1-BCF6-48E231E663EC Q35082412-662E3FB2-3EC6-400E-B2A6-1DB89CCDA292 Q35105257-F2BCF442-32EB-4C8A-9767-9E4AE4574F7D Q35109141-DB34BFDA-CCB5-4323-AD7C-CF92E2E35759 Q35114460-A6306E1C-9EAC-4DE5-9E72-B3FEAB6FDA7D Q35196950-21060A36-D51F-4C77-8D8B-D243140C2365 Q35334958-531FA7E0-DE1D-42A1-B45C-72DEB98B34A9 Q35377689-A3A85245-A0FA-4173-93C4-12D0F93D28F3 Q35628597-16B89B1C-504F-403E-9850-8D83F9C6B9E5 Q35640101-6D6D209E-6DA3-4CAA-9EE0-FAFDBC8AA653 Q35786155-D393D9F8-E0F5-4060-B583-81FADA320073 Q35892542-0D631040-5FAF-4D78-A3DF-CD51B5681225 Q35895174-3DE10100-F1D6-4A21-B61A-E9BB0BE42FAA

P2860

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

http://www.wikidata.org/entity/Q33627763

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I study of intravenous v ...... ts with advanced solid tumors.

@ast

Phase I study of intravenous v ...... ts with advanced solid tumors.

@en

type

label

Phase I study of intravenous v ...... ts with advanced solid tumors.

@ast

Phase I study of intravenous v ...... ts with advanced solid tumors.

@en

prefLabel

Phase I study of intravenous v ...... ts with advanced solid tumors.

@ast

Phase I study of intravenous v ...... ts with advanced solid tumors.

@en

P1433

Q33627763-B7CCCF28-2265-4BE3-BBEC-B01412414800

P1476

Q33627763-005AEB73-07DB-4A63-B085-C817B73EC621

P2093

Q33627763-0B21EC55-AE24-425A-9A83-0BA5FE6448E6

Q33627763-0F42DA9A-B715-4D30-9954-69182950862F

Q33627763-3AEF2F34-7B49-4E9D-A355-8207367CB07D

Q33627763-466488AD-C71C-4AE1-B2C0-BCF6FF3E1B1C

Q33627763-50AF593F-23D6-4B53-93A5-D38F3355D5A4

Q33627763-87E895B5-8BA6-4543-95AC-8A0E860850B3

Q33627763-8F21DBC4-2692-45AA-BCB8-C3C8918EA667

Q33627763-9BF6F2B1-0BEC-4448-BF0E-92B01FAD3E09

Q33627763-9DA5F65E-C4CF-4170-99D0-B77F8DC6A31C

Q33627763-A2AEB712-D6FC-421C-9087-4F5179B846C0

P2860

Q33627763-23B087D6-E8CC-4217-94D4-62DFDD110402

Q33627763-25683C5C-8803-4AE5-9AF2-01784650155D

Q33627763-2C86253D-466A-4A96-BD37-A4C2071E5FD3

Q33627763-30855872-1F08-40E2-AE45-1DD16A2C03C5

Q33627763-42084406-3288-42B6-8DAA-2349DE361398

Q33627763-6D23A3B7-B85F-40C7-82EC-AB02669FD5E4

Q33627763-7CC270B6-6C53-40B1-9F9C-8DEEDC532A26

Q33627763-957FBCC8-E895-43D8-9600-5315237EAB98

Q33627763-95DEDDB1-EED8-4134-B70C-335B2BAB5ABF

Q33627763-9960F3DF-4A93-494B-AE98-8BEBD3889920

P304

Q33627763-08C4549A-E60A-485A-8291-B53D9FFC1DFE

P31

Q33627763-006160D7-5659-4014-963F-FB5D67DC7FFA

P356

Q33627763-8EA00321-CBB4-499F-829D-D43BDBE2245B

P407

Q33627763-32B528B2-C674-4861-8E80-EB78D2C03AA3

P433

Q33627763-8E6CF2C5-974E-4737-9B38-C5A679769D66

P478

Q33627763-95260A5B-7786-4D67-85BF-41BFA662C77F

P50

Q33627763-BEB610D9-66A4-4D07-895C-ECFC3F4707B1

Q33627763-C39FD706-5E78-4940-8A29-0CB7BE821AAE

P577

Q33627763-781B9D7B-01C6-4691-8103-2C3504BED21C

P698

Q33627763-61B7A963-257E-4C37-804B-2D255CDF2C42

P921

Q33627763-6B9C6D6D-CE3C-4400-8A4F-6C0710BCF7EF

P932

Q33627763-12D6540B-115B-4197-B4E9-2E7D58DCF2A7

P356

JCO.2009.22.9237

P1433

Journal of Clinical Oncology

P1476

Phase I study of intravenous v ...... nts with advanced solid tumors

@en

P2093

A Craig Lockhart

http://www.w3.org/2001/XMLSchema#string

David R Spriggs

http://www.w3.org/2001/XMLSchema#string

Elizabeth Koehler

http://www.w3.org/2001/XMLSchema#string

Giliane Buzenet

http://www.w3.org/2001/XMLSchema#string

Isabelle Dancy

http://www.w3.org/2001/XMLSchema#string

Jakob Dupont

http://www.w3.org/2001/XMLSchema#string

Jason A Koutcher

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

Lars Sternas

http://www.w3.org/2001/XMLSchema#string

Lawrence H Schwartz

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Tumor angiogenesis

The biology of vascular endothelial growth factor

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

VEGF: an update on biological and therapeutic aspects.

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

P304

207-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.22.9237

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

David H. Gultekin

Edwin F. Donnelly

P577

2009-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19949018

http://www.w3.org/2001/XMLSchema#string

P921

P932

2815710

http://www.w3.org/2001/XMLSchema#string